Martin Donnelley, Patricia Cmielewski, Kaye Morgan, Juliette Delhove, Nicole Reyne, Alexandra McCarron, Nathan Rout-Pitt, Victoria Drysdale, Chantelle Carpentieri, Kathryn Spiers, Akihisa Takeuchi, Kentaro Uesugi, Naoto Yagi, David Parsons
Gene vectors to treat cystic fibrosis lung disease should be targeted to the conducting airways, as peripheral lung transduction does not offer therapeutic benefit. Viral transduction efficiency is directly related to the vector residence time. However, delivered fluids such as gene vectors naturally spread to the alveoli during inspiration, and therapeutic particles of any form are rapidly cleared via mucociliary transit. Extending gene vector residence time within the conducting airways is important, but hard to achieve...
May 30, 2022: Scientific Reports